Vanda Pharmaceuticals Charts Strategic Course with Key Pipeline Developments

Vanda Pharmaceuticals Inc. (Vanda) provided a comprehensive update on its strategic direction and drug development pipeline during the Cantor Global Healthcare Conference yesterday. The market response was muted, with shares trading at approximately $4.73 in the pre-market session today, reflecting a modest 24-hour gain of 0.64%.

The company is approaching several significant regulatory milestones that could substantially impact its future. The U.S. Food and Drug Administration (FDA) is set to make a decision on tradipitant for the treatment of motion sickness by December 30, 2025. Furthermore, a PDUFA date for Basanti, targeting bipolar disorder and schizophrenia, is scheduled for February 2026. The firm has an ambitious plan to launch up to six new products by 2026.

This aggressive expansion plan is underpinned by a Read more...